The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof. Chloe Investor Presentation Safe Harbor Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs, concerning future developments and their potential effects on Insulet. There can be no assurance that future devel ...

Exhibit 99.1 Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency ) 1 Raising Full Year Revenue and Gross Margin Guidance ACTON, Mass. - May 8, 2025 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended March 31, 2025. ® "Our first quarter results showcase the strong execution and dedication of the Insulet ...

Wall Street analysts forecast that Insulet (PODD) will report quarterly earnings of $0.81 per share in its upcoming release, pointing to a year-over-year increase of 11%. It is anticipated that revenues will amount to $541.33 million, exhibiting an increase of 22.6% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed t ...

Insulet (PODD) shares soared 7.2% in the last trading session to close at $264.72. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.Insulet recorded a strong price rise on investors’ optimism surrounding its impending first-quarter 2025 financial results, which is slated to release on May 8 post the closing bell. The Zacks Consensus Estimate for the first quarter revenue suggests a growth of 22.7 ...

Insulet Corporation (PODD) recently made its Omnipod 5 Automated Insulin Delivery (“AID”) system commercially available in Canada for people with type 1 diabetes (ages two years and above). Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 AID system for more people globally. PODD Stock’s Likely Trend Following the NewsFollowing the ann ...

Insulet Corporation (PODD) has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 Composite has increased 9.1%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Insulet develops, manufactures and markets the Omnipod System — an innovative, discreet and easy-to-use continuous insulin del ...

Insulet Corporation (PODD) recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 AID system for more people globally. PODD Stock’s Likely Trend Following the NewsFollowing the announcement on March 18, PODD’s shares climbed 2% to $265. ...

Insulet Corporation (PODD) announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”). Omnipod 5 is the only FDA-cleared, fully disposable pod-based automated insulin delivery ("AID") system. The RADIANT trial results demonstrate Omnipod 5 to be clinically efficient for people living with type 1 diabetes. The conference was held in Amsterdam, Netherlands.PODD Stock’s Likely Trend Following the NewsFollo ...

Company Overview - Insulet Corp (NASDAQ: PODD) operates in the health care sector, specializing in health care equipment, particularly insulin delivery systems like the Omnipod platform [1]. Investment Strategy - The company is of interest to individual investors looking to build financial assets for retirement, with strategies that include both long and short trading, as well as the use of inverse ETFs to capitalize on market declines [1]. Analyst Position - The analyst has a beneficial long position in PODD shares, indicating confidence in the company's future performance [2].

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].